AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03749148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: anti-IL4-Receptor alpha
Study NCT03749148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04210804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)
Description: 200mls Smoothie
Study NCT04210804 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Smoothie 1g Eicosapentaneoic Acid (EPA) and 1g Docoshaexanoic Acid (DHA)
Description: 200mls Smoothie
Study NCT00560586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 1 puff each nostril (32 micrograms) at bedtime
Study NCT00560586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 puff each nostril at bedtime
Study NCT04163835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal-dose Wenxin Granules
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g.
Study NCT04163835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1/2 Normal-dose Wenxin Granules
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g.
Study NCT04163835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Twice Normal-dose Wenxin Granules
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g.
Study NCT04163835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g.
Study NCT03293472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients \< 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle
Study NCT03293472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle
Study NCT03472976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqueous Cream B.P.
Description: Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
Study NCT03472976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
Study NCT03472976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04
Description: Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
Study NCT03334799 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sacroiliac belt
Description: standing and walking with the belt on and with the belt off
Study NCT01701271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hair loss prevention lotion
Description: For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
Study NCT02744027 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)
Description: Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories \[TWIST\]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
Study NCT02744027 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heavy Weighted T2 Imaging (T2W)
Description: Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.
Study NCT02744027 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lymph Node Access
Description: The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.~Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite.
Study NCT01361269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmidomycin and clindamycin
Description: The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
Study NCT01890213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX701
Study NCT00561470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
Study NCT00561470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
Study NCT00561470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Description: The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours
Study NCT00561470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
Description: The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~* 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~* 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~* 5-FU 2400 mg/m² continuous IV infusion over 46-hours
Study NCT04533191 — intervention group
Intervention type: PROCEDURE
Intervention: LAL IOL lens
Description: Standard of care Cataract surgery with IOL placement
Study NCT02987569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mConnect plus mobile connections to multidisciplinary professionals & peers
Description: mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
Study NCT02987569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iPad use plus one mobile connections to multidisciplinary professionals & peers
Description: iPad with a data plan and one professionally moderated iPad visual meeting with peers.
Study NCT04093791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collective Intervention G
Description: The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mothers. The operator maintains a nonjudgmental approach encouraging the women to describe the need for behavioral change.~2. Analysis. The situation must be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way and they will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mothers to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change.
Study NCT04093791 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Intervention I
Description: The steps are:~1. Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mother. The operator maintains a nonjudgmental approach encouraging the woman to describe the need for behavioral change.~2. Analysis. The situation have be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way, and she will assign a grade of discomfort for each problem.~3. Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mother to face problems and the reasons of the failures.~4. Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change.
Study NCT02115074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatine
Description: Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02115074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: Dose levels : 100 mg twice a day (\< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT01192113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin IV Injection
Description: Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks
Study NCT01192113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin IM injection
Description: Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks
Study NCT01192113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin IV or IM injection
Description: Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
Study NCT00771264 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgent PC Neuromodulation System
Description: The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
Study NCT01040936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
Study NCT01040936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
Study NCT05548998 — intervention group
Intervention type: OTHER
Intervention: General anesthesia with low fresh gas flow
Description: General anesthesia with a fresh gas flow lower than 1L/min for the maintenance phase of anesthesia
Study NCT05548998 — intervention group
Intervention type: OTHER
Intervention: General anesthesia with high fresh gas flow
Description: General anesthesia with a fresh gas flow equal to or higher than 1L/min for the maintenance phase of anesthesia
Study NCT05548998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mini mental state examination
Description: 6 category and 30-point test to inquire patient's cognitive function
Study NCT05548998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Analogue Scale
Description: The patient's self-reported pain intensity according to a visual scale between 0 and 100
Study NCT02293759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HoLEP
Description: Holmium laser enucleation of the prsotate
Study NCT02293759 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Greenlight laser PVP
Description: Greenlight laser (532nm) Photoslective vaporization of the prostate
Study NCT04506398 — intervention group
Intervention type: PROCEDURE
Intervention: liver transplant
Description: Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver.
Study NCT03292146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alendronate 70Mg Tab
Description: Alendronate 70mg PO weekly starting at Month 12 through 24 months.
Study NCT00993317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of CDP870
Description: Given every 2 weeks until Week22 (SC)
Study NCT04506398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA
Description: Circulating Tumor DNA Correlates With Microvascular Invasion and Predicts Tumor Recurrence of Hepatocellular Carcinoma
Study NCT04506398 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: whole exome sequencing
Description: xome sequencing analysis of liver tumors could reveal mutational signatures associated with specific risk factors of recurrence.
Study NCT01519297 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irbesartan
Description: 150mg orally for one dose
Study NCT00929474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickOpt - SJM CRT (Group 1)
Description: The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
Study NCT00929474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control - SJM CRT (Group 2)
Description: The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
Study NCT02788370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a conical positive expiratory pressure device
Description: The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).
Study NCT02788370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant work load cycling test
Description: Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~1. sever breathlessness (>5 /10 score of modified Borg scale)~2. leg fatigue (can not maintain speed between 50 to 60 rpm)~3. Hear rate (HR) >80 % age-predicted maximum HR~4. Exercise time up to 10 minutes~5. Other symptom that stated by American thoracic Society(2002)
Study NCT02788370 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Constant work load cycling test
Description: Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~1. sever breathlessness (>5 /10 score of modified Borg scale)~2. leg fatigue (can not maintain speed between 50 to 60 rpm)~3. Hear rate (HR) >80 % age-predicted maximum HR~4. Exercise time up to 10 minutes~5. Other symptom that stated by American thoracic Society(2002)
Study NCT03367559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROTAVAC®
Description: Rotavac® is in frozen form and is thawed till fully liquid prior to administration.
Study NCT01443494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NE
Description: norepinephine
Study NCT03989934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Mind in Action
Description: Mindfulness program for adolescents
Study NCT03989934 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Topics
Description: Health education program for adolescents
Study NCT01899807 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OssDsign AB
Study NCT03817957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucoferron
Description: intravenous administration
Study NCT03817957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: intravenous administration
Study NCT03817957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: oral administration
Study NCT00898599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Inulin type fructooligosaccharides
Study NCT00898599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin as placebo
Study NCT02631278 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative radiofrequency ablation
Description: Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
Study NCT02403349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Study NCT02403349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Study NCT02403349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Study NCT00061373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.
Study NCT00061373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tinzaparin sodium
Description: A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.
Study NCT00061373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptifibatide
Description: Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
Study NCT06618846 — intervention group
Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastric bypass
Description: This is the observational study that investigate the impact of laparoscopic Sleeve Gastrectomy (LSG) or laparoscopic Roux-en-Y Gastric Bypass on premature aging by the assesment of biological age markers (telomere lenght, IL-6, TNFalpha, total oxidative status, DNA damage, cognitive function)
Study NCT00772122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
Study NCT00772122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.